Case Study: HR+ Uptake, HNSCC Investment & Seasonal Spironolactone
Two patients, two diagnoses—one discovers modern HR+ targeted options, another finds renewed hope as HNSCC investment brings trials nearby. Seasonal shifts, spironolactone use in elders, and real-world tools change the way people connect with research.
Robert Maxwell
Oct 20, 2025
HR+ breast therapies
Head and neck SCC
Gynecologic cancer trials
Spironolactone geriatric studies
